PALM BEACH, Florida, November 16, 2016 /PRNewswire/ --
Increased funding due to overall market momentum is serving to aid biotech and pharma companies within medicinal cannabis sector to delve deeper into the research and development of cannabinoid prodrug pharmaceutical solutions. Biotech companies in the sector to watch include: Vitality Biopharma, Inc. (OTCQB: VBIO), GW Pharmaceuticals plc (NASDAQ: GWPH), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), INSYS Therapeutics, Inc. (NASDAQ: INSY) and NEMUS Bioscience, Inc. (OTCQB: NMUS).
Vitality Biopharma, Inc. (OTCQB: VBIO), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it is advancing its cannabosides pharmaceuticals for treatment of narcotic bowel syndrome, a severe form of opiate-induced abdominal pain.
Read the full Vitality Biopharma (VBIO) Press Release at http://marketnewsupdates.com/news/vbio.html
Every day more than 650,000 opioid prescriptions are dispensed by US pharmacies, resulting in over 200 million opioid prescriptions dispensed annually. Studies have reported that up to 81% of patients treated with opiates have functional bowel disorders, but these common symptoms may lead to underdiagnosis of opiate-induced severe abdominal pain. More than half (58%) of opiate users have reported chronic abdominal pain in independently-conducted clinical studies, and narcotic bowel syndrome is the most severe form of this disorder, where abdominal pain paradoxically increases despite continued administration of narcotics to treat the pain. When undiagnosed, patients or physicians continue to escalate dosages, which temporarily relieves pain, but leads to addiction and also worsens the abdominal pain - a vicious cycle. Narcotic bowel syndrome has dire consequences for opiate users, as their quality-of-life has been reported to be worse than patients with quadriplegia.
The clinical use of cannabinoids for resolving pain and inflammation is well established, including in large (n=313) independently-conducted clinical studies of inflammatory bowel disease, where 84% of patients reported an improvement in abdominal pain. Vitality's proprietary cannabosides enable the selective delivery of cannabinoids to the intestinal tract, enabling large concentrations of THC and CBD (Δ9-tetrahydrocannabinol and cannabidiol, respectively) to be delivered without any resulting psychoactivity.
In other sector related performances in yesterday's market and recent developments of note:
GW Pharmaceuticals plc (NASDAQ: GWPH) close up slightly on Tuesday on just over 1/2 Million shares traded by the market close. GW Pharmaceuticals, a biopharmaceutical company, together with its subsidiaries, engages in discovering, developing, and commercializing cannabinoid prescription medicines
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, earlier this month announced the enrollment of the first patients into the STAR 2 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial, an open-label extension trial which allows patients who have completed the STAR 1 clinical trial to receive treatment with ZYN002 CBD gel for up to 52 weeks.
INSYS Therapeutics, Inc. (NASDAQ: INSY) closed down slightly on Tuesday at $14.10 on just over 1/2 Million shares traded by the market close. Insys Therapeutics, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States.
NEMUS Bioscience, Inc. (OTCQB: NMUS) announced yesterday that significant data concerning the IOP lowering effect of NB1111 and duration of action will be presented at the 2016 AAPS National Meeting being held in Denver, Colorado on Today, November 16, 2016, at 8:30 a.m. (MST) by the company's research and commercialization partner, the University of Mississippi. The abstract, "Effect of single versus multiple day regimen of Δ9 -THC-valine-hemisuccinate (THCVHS) on the intra-ocular pressure (IOP) lowering activity in normotensive rabbits" (abstract # 30W0830), reports data comparing the Nemus prodrug of tetrahydrocannabinol (THCVHS) also known as NB1111, to established glaucoma therapies of Pilocarpine and Timolol, as well as standard Δ9 -THC in both emulsion and solid lipid nanoparticle (SLN) eye drops
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated one thousand nine hundred dollars for news coverage of the current press release issued by Vitality Biopharma, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Media Contact email: firstname.lastname@example.org - +1(561)325-8757